I-Lymphoma Australia yaphumelela ekutholeni uxhaso lomhlaba wonke oluvela kwa-AbbVie ukuze iqhube izingxoxo nochwepheshe base-Australia nabamazwe ngamazwe ku-lymphoma kanye ne-chronic lymphocytic leukemia (CLL). Izingxoxo zizobika ulwazi lwakamuva mayelana nokuhlolwa komtholampilo kwe-lymphoma/CLL kanye nezifundo ezivela emhlabeni wonke futhi zethulwe phakathi nomhlangano we-ASH. Lezi zingxoxo zizokwabiwa emhlabeni wonke ngokusebenzisa amaqembu amelela iziguli.
I-Lymphoma Australia yenza izingxoxo ezicishe zibe ngu-40 phakathi nezinsuku ezi-4 zomhlangano futhi sithanda ukudlulisa ukubonga okusuka enhliziyweni okuvela kumphakathi we-lymphoma/CLL kuwo wonke umuntu owabelane nathi ngesikhathi sakhe, ulwazi nobungcweti.
I-B-cell Lymphoma
UDkt Laurie Sehn – ASH Lymphoma Updates.
UDkt Laurie Sehn waseBritish Columbia Cancer Centre waseVancouver, eCanada unguSihlalo webhodi labeluleki bezokwelapha le-International Lymphoma Coalition. UDkt Sehn uxoxisane ngezinye zezinto ezigqamile ezindleleni zokwelapha ezinoveli ezethulwa ngesikhathi somhlangano we-ASH we-lymphoma. Lokhu kuhlanganisa i-Polatuzumab (i-antibody conjugate yesidakamizwa) yokusabalalisa i-B-cell lymphoma (DLBCL) enkulu ne-Mosunetuzumab – (i-bispecific antibody) esetshenziselwa i-B-cell non-Hodgkin lymphomas.UDkt Chan Cheah – Isigaba I Study TG-1701 Relapsed or Refractory B-cell Lymphoma.
U-A/Prof Chan Cheah, onguchwepheshe wezifo zenhliziyo, uSir Charles Gairdner Hospital, iHollywood Private Hospital & Blood Cancer Research WA, ePerth, eWestern Australia, uxoxe ngesethulo sephosta ku-ASH sohlolo olwaqhutshwa e-Australia kusetshenziswa iTyrosine Kinase yesizukulwane esisha iBruton. I-(BTK) inhibitor ebizwa nge-TG-1701 esetshenziswa ezigulini ezine-relapsed/refractor B-cell malignancies. Le mithi yomlomo inikezwa njenge-ejenti eyodwa ngokuhlangana ne-umbralisib (PI3K inhibitor) kanye ne-ubiltuximab (i-glycoengineered anti-CD20 monoclonal antibody).UDkt George Uyalandela - Ukuvuselelwa Kwe-Lymphoma.
UDkt George Follows uyi-Lymphoma/CLL Clinical Lead yase-Cambridge futhi ubamba izikhundla eziningana okuhlanganisa nosihlalo weforamu ye-UK CLL. UDkt Follows uxoxisane ngezibuyekezo ze-lymphoma ezethulwe ngesikhathi somhlangano we-ASH wezintshisekelo. Lokhu kufaka phakathi ukuhlolwa kwesigaba I kusetshenziswa umuthi omusha obizwa ngokuthi i-Monunetuzumab okuyi-bispecific monoclonal antibody eqondise i-CD3 ne-CD20 futhi okuholele ekuphenduleni okuhlala isikhathi eside ezigulini ezine-B-cell non-Hodgkin lymphoma ebuyele emuva noma erefractory, okuhlanganisa neziguli ezibuyelwe yi-CAR T. -ukwelashwa kwamaseli.
UDkt Stephen Schuste - I-Mosunetuzumab yenza ukukhululwa okuphelele okuhlala isikhathi eside ezigulini ezine-B-cell non-Hodgkin lymphoma.
I-bispecific monoclonal antibody i-Mosunetuzumab, eqondise i-CD3 ne-CD20, iholele ekuphenduleni okuhlala isikhathi eside ezigulini ezine-B-cell non-Hodgkin lymphoma (NHL), ngisho nakulezo ezazinesifo esasibuyele emuva noma esingavumelani ne-chimeric antigen receptor (CAR) T- ukwelashwa kwamaseli. UDkt Schuste uxoxa ngocwaningo oluqhubekayo lwesigaba se-I/Ib (GO29781; NCT02500407) se-mosunetuzumab ezigulini ezine-B-cell non-Hodgkin lymphoma (NHL), ezibuyelwe kabusha/ezilahliwe (R/R) ekwelashweni kwe-CAR-T noma labo ukubambezeleka ekwelashweni okusebenzayo ayifaki le ndlela. Usekelo lwedatha yokuqala yokuthi i-mosunetuzumab inokubekezeleleka okuhle nokusebenza okuqinile ku-R/R B-cell NHL ephethwe kakhulu.
UDkt John Leonard - ugqamisa emhlanganweni we-lymphoma.
UDkt Leonard uxoxe ngemibono yakhe yochwepheshe evela ezethulweni ze-lymphoma ngesikhathi somhlangano. Uxoxe ngezihloko ezimbalwa ezihlanganisa: • I-Follicular lymphoma – i-chemo free regimens • Ukusabalalisa i-Large B-cell Lymphoma – impilo yamathambo ezigulini ezingemva kwe-R-CHOP kanye ne-CAR T-cell therapy • I-Mantle Cell Lymphoma – imithi emisha ehlanganiswe ne-chemotherapy • Ukuhlolwa kwegazi kwe-DNA • Imithi yokugomela i-lymphoma
I-Chronic Lymphocytic Leukemia (CLL) & I-Lymphocytic Leukemia Encane (SLL)
UDkt Brian Koffman - Izibuyekezo ze-CLL kanye nokumela isiguli.
UDkt. Koffman, udokotela owaziwayo, uthisha kanye noprofesa wezokwelapha owaphenduka isiguli se-CLL, uzinikele ekufundiseni nasekusizeni umphakathi we-CLL kusukela ekuxilongweni kwakhe ngo-2005. UDkt. ulwazi nokuqonda okumvumela ukuba anikeze izincazelo ezicacile zezinkinga eziyinkimbinkimbi futhi amelele iziguli akanye nazo futhi azise abahlinzeki bezempilo akanye nabo. Lokhu kubaluleke kakhulu uma kubhekwa indlela yokwelapha eshintsha ngokushesha. UDkt Koffman ungumsunguli we-CLL Society, e-USA. UDkt Koffman uxoxe ngezibuyekezo ze-CLL ezivela engqungqutheleni okuhlanganisa nezibuyekezo mayelana nokwelashwa kwe-CAR T-cell, i-ibrutinib, i-acalabrutinib, ukulandelana kwemithi kanye nokwelashwa okuhlangene okuhlukile. Ubuye waxoxa ngokuphathwa okungcono kakhulu kwe-CLL, okuhlanganisa ukuhlolwa kofuzo ngaphambi kokwelashwa kanye nalezo ziguli ezinezifo ezingaguquki, i-17p del akufanele ibe ne-chemotherapy, kunalokho ukwelashwa okuhlosiwe.
USolwazi John Gribben kanye noDeborah Sims – Uhlolojikelele lokwelashwa kwe-CLL.
USolwazi Gribben uxoxisane ngombono wakhe ngezibuyekezo ezivela emhlanganweni lapho izethulo eziningi zigcizelele ukuthi imithi yokwelapha esetshenziswayo mihle njengoba sekunesikhathi eside ilandelwa. Ngokulandela isikhathi eside kufika nolwazi lobuthi obusha obungase buvele. Singakwazi ke ukufundisa iziguli kangcono ngokuba nombono ongcono wokuthi yini ongayilindela. Ubuye waxoxa ngemithi yokwelapha yenoveli yesizukulwane esisha eyethulwa, hhayi ku-CLL kuphela, kodwa namanye ama-lymphoma afana ne-Follicular lymphoma & Mantle cell lymphoma. Kukhona futhi izinhlolo eziningi zokwelashwa zesigaba sasekuqaleni ezinemithi emisha ebonisa isithembiso. Ukukhathazeka okulandelayo ukuthi ngalezi zindlela zokwelapha ezisanda kuzalwa kanye nenhlanganisela yokwelapha, kuza nezindleko ezengeziwe zezinhlelo zezempilo.
UProf Stephan Stilgenbauer noDeborah Sims – Izibuyekezo ngokuphathwa kwe-CLL/SLL.
UProf Stilgenbauer unikeze isifinyezo sezibuyekezo zokwelashwa kweziguli ezine-CLL/SLL emhlanganweni we-ASH. Uxoxa ngokusetshenziswa kwezindlela zokwelapha ezisanda kuzalwa njengama-ejenti angawodwa kanye nezinhlanganisela ezinemiphumela ebalulekile ezigulini, ikakhulukazi lezo ezinesifo esingaguquki futhi ngenxa yalokho ezingaphenduli ekuphathweni kwendabuko okusekelwe ngamakhemikhali. Ukwelashwa kwesikhathi esizayo kwe-CLL/SLL kungase kube ukuthi i-chemotherapy ingase ibe ukwelashwa komugqa wesibili noma wesithathu.
A/Prof Constantine Tam kanye noDeborah Sims – CLL & Mantle Cell Lymphoma.
A/Prof Constantine Tam, Peter MacCallum Cancer Centre, RMH & St Vincent's Hospital bakhulume noDeborah Sims, waseLymphoma Australia. UDkt Tam unikeza ukuqonda kwakhe emaphuzu avelele emhlanganweni we-CLL kanye ne-Mantle cell lymphoma. Unikeze uhlaka lwezethulo zakhe ezi-3 ezinconywe kakhulu zeChronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL).
UDkt George Uyalandela - izibuyekezo ze-CLL.
UDkt George Follows wase-UK ukhulume neLymphoma Australia emhlanganweni we-American Society of Hematology (ASH) osanda kuba se-Orlando, e-USA. UDkt Follows uyi-Lymphoma/CLL Clinical Lead yase-Cambridge futhi ubamba izikhundla eziningana okuhlanganisa nosihlalo weforamu ye-UK CLL. Uxoxe ngezibuyekezo zocwaningo lwakamuva nemiphumela yocwaningo eyethulwe emhlanganweni we-ASH ku-CLL.
UDkt Nitin Jain noDeborah Sims - Ibrutinib & Venetoclax ezigulini ezine-CLL.
UDkt Nitan Jain uyiNhlangano Yosolwazi eMnyangweni Wegazi Leukemia eNyuvesi yaseTexas MD Isikhungo Somdlavuza sase-Anderson e-Houston, e-Texas, e-USA. UDkt Nitan uxoxisane ngezethulo zakhe ezi-2 phakathi nomhlangano we-ASH wezifundo ezi-2 ezenziwa e-MD Anderson Cancer Center kusetshenziswa i-Ibrutinib ehlanganisiwe ne-venetoclax neziguli ezine-lymphocytic leukemia (CLL) ezigulini zombili zomugqa wokuqala kanye nalezo ezinesifo esibuyele emuva/esiphikayo. Imiphumela yabonisa ukuthi kuwo womabili la maqembu ukwelashwa okuhlangene kusetshenziswa i-ibrutinib ne-venetoclax kuwumuthi osebenzayo womlomo wamahhala we-chemotherapy weziguli ezine-CLL futhi izifundo ezengeziwe zizoqhubeka.
UDkt Tanya Siddiqi – I-CAR T-cell ku-CLL ephinde yabuyela emuva/eyisakhi.
UDkt Tanya Siddiqi unguMqondisi, Uhlelo lwe-Chronic Lymphocytic Leukemia, i-Toni Stephenson Lymphoma Centre kanye no-A/Prof Department of Hematology & Hematopoietic Transplantation e-City of Hope National Medical Centre, e-Duarte, e-USA. UDkt Siddiqi uxoxisane ngesethulo sakhe ngesikhathi somhlangano wesigaba I sokwelapha iziguli ezibuyele emuva noma eziphikayo nge-CLL. Zonke iziguli ngaphambilini zazithole okungenani ukwelashwa okujwayelekile okungu-3, okuhlanganisa i-ibrutinib kanye nengxenye yeziguli nayo yayithole i-venetoclax. Ucwaningo lwelapha iziguli ezingama-23 ngokwelashwa kwe-CAR T-cell lapho abangaphezu kuka-80% bathole izimpendulo ezihlala isikhathi eside ezinyangeni eziyisi-6. Ukulandelela kuyaqhubeka.
USolwazi John Seymour – Isifingqo socwaningo lwase-Murano – CLL/SLL.
USolwazi Seymour wethule ukuhlaziya kweminyaka emine yocwaningo lwe-Murano oluqinisekisa inzuzo eqhubekayo ye-Venetoclax ne-rituximab ekhawulelwe ye-relapsed or refractory chronic lymphocytic leukemia (CLL). I-Venetoclax (i-Ven) i-oral inhibitor ekhetha kakhulu ye-key apoptosis regulator BCL-2, evezwe ngokweqile ku-CLL. I-MURANO (ucwaningo lweSigaba III olungahleliwe) luqhathanise ubude besikhathi esinqunyiwe i-VenR ne-bendamustine-rituximab evamile (BR) ku-R/R CLL. Ukusinda okuphezulu kwe-progression-free (PFS) ye-VenR iqhathaniswa ne-BR yasungulwa ekuhlaziyweni okuhleliwe kokuqala (Seymour et al. N Engl J Med 2018); inzuzo eqhubekayo ye-PFS ibonakale ngokulandelwa isikhathi eside nangemva kokuba zonke iziguli seziqedile ukwelashwa.
USolwazi Peter Hillmen – Izinselelo endaweni yokwelapha ye-CLL/SLL.
UProf Hillman uxoxa ngezinye zezinselelo zendlela yokwelapha eshintsha ngokushesha ye-CLL/SLL ngemithi yokwelapha emisha emakethe.
USolwazi Peter Hillmen - izibuyekezo ze-CLL ezivela ku-ASH 2019.
USolwazi Hillmen uxoxe ngezinye zezinto ezivelele ezibaluleke kakhulu zomhlangano wezivivinyo zokwelapha ezinoveli ezisetshenziswe endaweni yokuqala ezethulwa ezabonisa imiphumela emihle ngokusetshenziswa kwe-ibrutinib (BTK inhibitor), i-acalabrutinib (isizukulwane esisha se-BTK inhibitor), i-venetoclax (BCL2 inhibitor). ) kanye nokusetshenziswa kwezindlela zokwelapha ezihlangene. Uphinde waxoxa ngezivivinyo zemitholampilo esimeni esibuyele emuva esibonisa imiphumela emihle ehlanganisa ukwelashwa kwe-CAR T-cell. Siyabonga kuLeukemia Care ngokwabelana ngengxoxo neLymphoma Australia.
USolwazi Miles Prince – Ukuhlolwa kofuzo (CLL/SLL) kanye nokwelashwa kwe-CAR T-cell.
USolwazi Prince uxoxe ngemibono yakhe ngezihloko ezibalulekile ze-lymphoma emhlanganweni. Uxoxe ngokuthi indlela engcono yokwelapha i-lymphoma yesiguli, ukuxilongwa kwaso kufanele kuqondwe futhi kwaziwe ngokugcwele. Kuye kwaboniswa ukuthi iziguli ezitholakala zine-CLL/SLL zidinga ukuhlolwa kofuzo ngaphambi kokuthola ukwelashwa. Iziguli ezingashintshile kanye ne-TP53 eguqule i-CLL/SLL, ukwelashwa ngamakhemikhali kuboniswe kungasebenzi kuleli qembu lesiguli. E-USA nase-UK (nakwamanye amazwe aseYurophu) iziguli zixhaswa ngezimali ukuze zithole i-Ibrutinib ehamba phambili, nokho lokhu akukabi njalo e-Australia, lapho iziguli zithola i-chemo-immunotherapy kanye ne-ibrutinib ekwelashweni komugqa wesibili.
Sabalalisa I-B-cell Lymphoma Enkulu (DLBCL)
A/Prof Chan Cheah – Aggressive Lymphoma, Diffuse Large B Cell lymphomas.
U-A/Prof Cheah ubuyekeza iphepha elithi “Aggressive Lymphoma (Diffuse Large B-cell kanye namanye ama-b-cell non-Hodgkin lymphomas anolaka) - imiphumela evela ezivivinyweni zomtholampilo ezizoba khona: iseshini yokuthuthukisa i-frontline chemotherapy” eyayibanjwe ngeSonto zingama-8 kuZibandlela e-ASH 2019.
UDkt Jason Westin – Ukusabalalisa izibuyekezo ezinkulu ze-B-cell Lymphoma kanye neSifundo Sokuqala Esihlakaniphile.
UDkt Westin uxoxe ngezinye zezinto ezivelele engqungqutheleni eyayise-DLBCL okuhlanganisa nokwelashwa kwe-CAR T-cell kanye nezibuyekezo ezivela ezifundweni ezisebenzisa ukwelapha ngamakhemikhali amancane futhi ngaleyo ndlela kuthuthukiswe imiphumela emibi enobuthi ezigulini.
I-Follicular Lymphoma
UDkt Loretta Nastoupil - Ucwaningo lwe-Follicular lymphoma - Ingxenye 1.
UDkt Nastoupil exoxa ngemiphumela yocwaningo lwakhe lwesigaba II se-Obintuzumab (uhlobo lwe-II anti-CD20 monoclonal antibody) kanye ne-Lenalidamide (i-immunomodulatory agent) ku-FL eyayingazange ilashwe, isimila esiphezulu. Le nhlanganisela yezindlela zokwelapha ibonakale ibekezelelwa kahle futhi isebenza kahle ocwaningweni lwangaphambilini lweziguli eziphathwe ku-FL ebuyele emuva noma ephikisayo.
UDkt Loretta Nastoupil - Ucwaningo lwe-Follicular lymphoma - Ingxenye 2.
UDkt Nastoupil uxoxe ngemiphumela yocwaningo lwakhe lwesigaba II se-Obintuzumab (uhlobo lwe-II anti-CD20 monoclonal antibody) kanye ne-Lenalidamide (i-immunomodulatory agent) ku-FL eyayingazange ilashwe, isimila esiphezulu. Ucwaningo olwengeziwe lwale ndlela yokwelapha ephumelelayo, yokuzivikela komzimba ku-FL engalashwa kuyafaneleka. UDkt Nastoupil uxoxa ngezizathu zale ndlela ephumelelayo nebekezelelwa kahle kunoma yisiphi isibalo seziguli ezine-Follicular lymphoma.
A/Prof Chan Cheah – Ukubuyekezwa kwesilingo somtholampilo se-Follicular lymphoma.
UDkt Cheah uxoxe ngesethulo esinikezwe uDkt Loretta Nastoupil ovela ku-MD Anderson Cancer Centre, eTexas phakathi nomhlangano we-ASH 2019. Ucwaningo lwesigaba II lubheke ekwelapheni iziguli ze-Follicular lymphoma ezazingazange zilashwe ngaphambili nge-Obintuzumab (uhlobo lwe-II anti-CD20 monoclonal antibody) kanye ne-Lenalidamide (i-immunomodulatory agent), enomthwalo omkhulu wesimila. Le nhlanganisela yezindlela zokwelapha ibonakale ibekezelelwa kahle futhi isebenza ngempumelelo ocwaningweni lwangaphambilini lweziguli ezelashwe nge-FL ebuyelwe kabusha noma eyeqisayo olwenziwa e-MD Anderson Cancer Center nguProf Nathan Fowler (ucwaningo OKUPHATHELELE).
UDkt Allison Barraclough -Nivolumab + Rituximab ku-First-line Follicular Lymphoma.
UDkt Barraclough uxoxe ngemiphumela yesikhashana yocwaningo lokuqala lwesigaba II somhlaba, oluholwa uDkt Eliza Hawkes, ophethe iziguli ezine-stage 1-3A follicular lymphoma. Ucwaningo lusebenzisa indlela yokwelapha ehlangene yokuzivikela komzimba kuphela, eyake yazanywa kuphela esimweni esiphinde sabuyela emuva. Iziguli zithola i-nivolumab kuphela emasontweni okuqala angu-8 futhi uma zithola impendulo ephelele, zizoqhubeka ne-ejenti eyodwa i-nivolumab. Kulabo abathole impendulo eyingxenye kuphela bangaqhubeka nokuba nenhlanganisela ku-nivolumab ne-rituximab. Imiphumela ibe mihle ngenani lokuphendula eliphelele (ORR) lama-80% futhi ngaphezu kwengxenye yalezi ziguli zithole impendulo ephelele (CR). Kwakukhona iphrofayili yobuthi obuphansi, lapho iziguli eziningi zazisakwazi ukusebenza futhi ziqhubeke nemisebenzi evamile yokuphila
UMantle Cell Lymphoma
UDkt Sasanka Handunetti – Mantle Cell Lymphoma (Ukubuyekezwa kocwaningo lwe-AIM).
UDkt Handunetti uxoxe ngesethulo sakhe mayelana nesibuyekezo seminyaka emithathu socwaningo lwesigaba II se-AIM (TAM, et al, NEJM 2018) olwenziwa e-Peter MacCallum Cancer Center eMelbourne, kusetshenziswa inhlanganisela ye-BTK inhibitor ibrutinib kanye ne-BCL-2 inhibitor venetoclax therapy ezigulini ezinomdlavuza. i-prognosis embi ye-mantle cell lymphoma (MCL). Imiphumela ibonise ukuqhubeka kwe-median ukusinda kwamahhala kwezinyanga ezingama-29. Kuphakamise umbuzo wokuthi kukhona ithuba lokwelashwa kwe-ejenti eqondisiwe yesikhathi esilinganiselwe ekuphathweni kwe-MCL ebuyele emuva noma ephikisayo.
USolwazi Steven Le Gouill – Ucwaningo lwe-Mantle Cell Lymphoma.
USolwazi Le Gouill uxoxe ngesigaba sakhe sokuqala socwaningo lwe-MCL esanda kutholakala esebenzisa i-Ibrutinib, i-Venetoclax ne-Obintuzumab konke okuye kwaboniswa ngaphambili ukuthi kuyasebenza esimweni esibuyele emuva/esiphikisayo njengama-ejenti angashadile futhi ahlanganiswe ku-MCL ebuyele emuva/ephikisayo (R/R) . Ubuye wanikeza umbono omfishane wezinga lokunakekelwa kweziguli ezine-MCL esigulini esincane kanye nesiguli esidala kukho kokubili umugqa wangaphambili kanye nokuphathwa kwe-R/R.
UProf Simon Rule - Ukuvuselelwa kwe-Mantle Cell Lymphoma.
UProf Simon Rule uxoxisane ngesethulo sakhe sephosta emhlanganweni ebheka ukulandelwa kweminyaka engu-7.5 kweziguli ezine-MCL ebuyele emuva noma ephikisayo iziguli ezisebenzisa i-ibrutinib (BTK inhibitor) ezibonise inani elikhulu leziguli ezisaxolelwe ngaphezu kweminyaka engu-5. Iphinde yabonisa ukuthi iziguli ezathola i-Ibrutinib emigqeni yokwelapha yangaphambili zinempendulo engcono ehlala njalo, kunalezo ezithole i-lateistique.
I-KTE-X19: Inketho Ye-CAR T-Cell Ye-Mantle Cell Lymphoma?
Amaphesenti angamashumi ayisishiyagalolunye nantathu eziguli ezine-reflexed/refractory mantle cell lymphoma (MCL) ziphendule ekwelashweni nge-KTE-X19, i-autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, ngokwemiphumela yocwaningo lwe-ZUMA-2 eyethulwa. eMhlanganweni Waminyaka yonke we-ASH wezi-2019.
I-Hodgkin Lymphoma
UDkt Jessica Hochberg – Chemotherapy, Intsha Abadala & Hodgkin Lymphoma.
Amazinga okwelapha e-Hodgkin Lymphoma esanda kutholakala aphakeme ngokusetshenziswa okuhlangene kwe-chemoradiotherapy. Kodwa-ke, lokhu kuvame ukuholela ekusebenzeni okungalungile ngokomzimba nangokwengqondo okungase kube nomthelela omkhulu kukhwalithi yempilo phakathi kwabasindile. Ukwengezwa kwe-Brentuximab vedotin ne-Rituximab ku-chemotherapy ehambisana nengozi (ngaphandle kwe-cyclophosphamide, etoposide noma i-bleomycin) ye-Hodgkin Lymphoma esanda kutholakala ibonakala iphephile ezinganeni, intsha kanye nabantu abadala. Imiphumela yethu ibonisa isithembiso esibalulekile ngezinga le-CR elingu-100%, u-58% wokusabela kwangaphambi kwesikhathi ngokushesha kanye nokuncipha okukhulu kokusetshenziswa kwe-chemotherapy enobuthi nemisebe. I-EFS/OS kuze kube manje ingu-100% ngesikhathi sokulandelela esimaphakathi esingaphezu kweminyaka engu-3.5.
USolwazi Andrew Evens – HoLISTIC Hodgkin Lymphoma International Study.
USolwazi Evens uyilungu elikhuthele le-HoLISTIC (Hodgkin Lymphoma International Study for Individual Care) - inhlangano yamazwe ngamazwe ehlanganisa ithimba lochwepheshe abahlukahlukene abavela emhlabeni wonke ukuze bahlole izici eziphawulekayo ze-Hodgkin lymphoma prognosis, isifo esiwumshayabhuqe, ukwelashwa, ukusinda kanye nemiphumela yezempilo. kuwo wonke amaqembu eminyaka. Bavumelanisa idatha yesiguli ngasinye evela ezinhlolweni zemitholampilo zesimanje ezingaphezu kuka-20 ezivela eNyakatho Melika naseYurophu yazo yonke iminyaka yobudala kanye nezikhungo eziyisi-6 nezifunda ze-Hodgkin lymphoma registries, kanye nomkhuba omkhulu we-oncology womphakathi. Umgomo wabo uwukuthuthukisa ukuthathwa kwezinqumo kweziguli nabahlinzeki be-Hodgkin lymphoma yezingane kanye nabantu abadala, uma kubhekwa izindlela zokwelapha ezikhulayo futhi kungekho datha ephelele yesikhathi eside yokubikezela.
UDkt Stephen Ansell noDeborah Sims – Hodgkin Lymphoma.
UDkt Ansell unguchwepheshe oholayo ku-non-Hodgkin lymphoma kanye ne-Hodgkin lymphoma eMayo Clinic, e-USA. UDkt Ansell ukhulume ngeseshini yokwelapha i-Hodgkin lymphoma - front line therapy kwa-ASH ayesanda kuyihambela. Iseshini yaqokomisa isilingo somtholampilo lapho kuphinde kwasetshenziswa khona izindlela zokwelapha ezintsha endaweni engaphambili, lapho kwenezela i-Brentuximab Vedotin ne-PD-1 inhibitor nokunciphisa enye ye-chemotherapy ejwayelekile eyayiyi-bleomycin, kubonise imiphumela evelele. Imiphumela iphinde yehlisa ubuthi ezigulini ezithola lokhu kwelashwa uma kuqhathaniswa nokwelashwa okujwayelekile. Ukwelashwa okujwayelekile ku-Hodgkin lymphoma kunezinga eliphezulu lokuphendula lapho cishe ama-90% eziguli efinyelela impendulo ephelele ye-metabolic. Izinhlolo eziningi ku-Hodgkin lymphoma okwamanje zihloselwe ukwehlisa iphrofayili yobuthi kanye nemiphumela yakamuva yalezi ziguli.
I-Marginal Zone Lymphoma
UDkt Sasanka Handunetti – Isigaba II Socwaningo Lwe-Relapsed or Refractory Marginal Zone Lymphoma.
UDkt Handunetti uxoxe ngesethulo sephosta esivela eqenjini e-Peter MacCallum Cancer Centre ngesikhathi somhlangano wokusetshenziswa kwe-ibrutinib ngokuhlanganiswa ne-venetoclax ezigulini ezine-Marginal Zone Lymphoma (MZL) ephindaphindiwe noma ephikisayo. I-MZL iyinkinga engelapheki ukuthi ayikho indinganiso yokwelashwa kokunakekelwa esimweni esibuyele emuva noma esiphikisayo. Yomibili le mithi ibonakale inobufakazi bokusebenza nokubekezelelana njengama-monotherapies (ama-ejenti angawodwa) futhi lolu cwaningo luhlose ukuhlola impendulo njengendlela yokwelapha ehlangene.
I-Central Nervous System Lymphoma
UDkt Katherine Lewis – Primary Central Central Nervous System Lymphoma (PCNSL).
UDkt Lewis uxoxe ngesethulo sephosta ku-ASH 2019 esibheka imiphumela yeziguli ezinesistimu yezinzwa eyinhloko noma yesibili (ubuchopho nomgogodla) i-lymphoma ephathwa nge-Ibrutinib (BTK inhibitor). Lena i-lymphoma engavamile futhi enolaka lapho leli qembu lesiguli linesifo esibi esivame ukwelapha ngemithi yokwelapha ngamakhemikhali eyinhlanganisela eqinile. Lolu kwakuwucwaningo lokubheka emuva olwaqoqa ulwazi oluvela kulo lonke elase-Australia naseNew Zealand lweziguli eziyi-16 ezalashwa nge-monotherapy Ibrutinib esimweni esibuyelelwe emuva/esiphikisayo. Nakuba inani elincane leziguli, imiphumela yayithembisa, ngezinga lokuphendula elifika ku-81%.
I-Macroglobulinemia ye-Waldenstrom
USolwazi Mathias Rummel – Macroglobulinemia ka-Waldenstrom kanye nokuhlolwa kwe-StiL.
Ihlanganisa imiphumela yeminyaka engu-2 ngemva kocwaningo lwe-StiL olubheka ukugcinwa kwe-Rituximab vs observation post bendamustine-rituximab. Imiphumela ibonisa ukuthi i-rituximab yesondlo ayithuthukisi ukuphila kwakho konke. UProf Rummel uphinde anikeze isifinyezo sokuphathwa kwamanje kwe-WM.
I-T-cell Lymphoma
I-Peripheral T-cell Lymphoma
UDkt Jasmine Zain, MD - uxoxa ngezifundo ezihlaba umxhwele kakhulu ku-PTCL ezethulwa ngo-ASH 2019.
(Siyabonga ku-OBRoncology).
UDkt. Zain, uMqondisi woHlelo lwe-T-cell Lymphoma, uMnyango Wezokwelashwa Kwegazi kanye Ne-Hematopoietic Cell Transplantation, i-Toni Stephenson Lymphoma Centre, i-City of Hope, ixoxa ngezifundo ezihlaba umxhwele kakhulu ekwelapheni i-peripheral T-cell lymphoma (PTCL) eyethulwa kwa-ASH. 2019.
UDkt Jasmine Zain – Ukuthi ukwelashwa kwe-peripheral T-cell lymphoma kuye kwavela kanjani.
(Siyabonga ku-OBRoncology).
UDkt. Zain, uMqondisi woHlelo lwe-T-cell Lymphoma, uMnyango We-Hematology kanye Ne-Hematopoietic Cell Transplantation, i-Toni Stephenson Lymphoma Centre, i-City of Hope, ubheka ukuthi i-peripheral T-cell lymphoma (PCL) yokwelapha iye yavela kanjani eminyakeni yamuva.
UDkt Jasmine Zain – Izindlela ezinoveli zokwelapha i-PTCL okuhlanganisa nokwelashwa kwe-CAR T-cell.
(Siyabonga ku-OBRoncology).
UDkt Zain, uMqondisi we-T-cell Lymphoma Programme, uMnyango we-Hematology kanye ne-Hematopoietic Cell Transplantation, i-Toni Stephenson Lymphoma Centre, i-City of Hope, usitshela ngezinye zezindlela zenoveli ekuthuthukisweni kokwelashwa kwe-peripheral T-cell lymphoma ( PTCL).
UDkt Timothy Illidge, uchaza inhloso yokukhomba i-PTCL.
(Siyabonga ku-OBRoncology).
UDkt. Illidge, uProfesa we-Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, uchaza injongo yokukhomba i-peripheral t-cell lymphoma (PTCL).
